Standout Papers

Antithrombotic Therapy for Venous Thromboembolic Disease 2006 2026 2012 2019 1.4k
  1. Antithrombotic Therapy for Venous Thromboembolic Disease (2008)
    Clive Kearon, Susan R. Kahn et al. CHEST Journal
  2. Apixaban for Extended Treatment of Venous Thromboembolism (2012)
    Giancarlo Agnelli, Harry R. Büller et al. New England Journal of Medicine
  3. Pulmonary Arterial Hypertension (2009)
    David B. Badesch, Gary E. Raskob et al. CHEST Journal
  4. Global Burden of Thrombosis (2016)
    Aaron M. Wendelboe, Gary E. Raskob Circulation Research
  5. Grading Strength of Recommendations and Quality of Evidence in Clinical Guidelines (2006)
    Gordon Guyatt, David D. Gutterman et al. CHEST Journal
  6. Hemorrhagic Complications of Anticoagulant Treatment (2001)
    Mark N. Levine, Gary E. Raskob et al. CHEST Journal
  7. American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer (2007)
    Gary H. Lyman, Alok A. Khorana et al. Journal of Clinical Oncology
  8. Thrombosis (2014)
    Gary E. Raskob, Pantep Angchaisuksiri et al. Arteriosclerosis Thrombosis and Vascular Biology
  9. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial (2010)
    Michael R. Lassen, Gary E. Raskob et al. The Lancet
  10. Continuous Intravenous Heparin Compared with Intermittent Subcutaneous Heparin in the Initial Treatment of Proximal-Vein Thrombosis (1986)
    Russell D. Hull, Gary E. Raskob et al. New England Journal of Medicine
  11. Different Intensities of Oral Anticoagulant Therapy in the Treatment of Proximal-Vein Thrombosis (1982)
    R. Hull, J. Hirsh et al. New England Journal of Medicine
  12. Subcutaneous Low-Molecular-Weight Heparin Compared with Continuous Intravenous Heparin in the Treatment of Proximal-Vein Thrombosis (1992)
    Russell D. Hull, Gary E. Raskob et al. New England Journal of Medicine
  13. Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement (2009)
    Michael R. Lassen, Gary E. Raskob et al. New England Journal of Medicine
  14. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies (2013)
    Martin H. Prins, Anthonie WA Lensing et al. Thrombosis Journal
  15. Thrombosis: a major contributor to the global disease burden (2014)
    Gary E. Raskob, Pantep Angchaisuksiri et al. Journal of Thrombosis and Haemostasis
  16. The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs (2015)
    Scott D. Grosse, Richard E. Nelson et al. Thrombosis Research

Immediate Impact

1 from Science/Nature 118 standout
Sub-graph 1 of 10

Citing Papers

Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture
2023 Standout
Milvexian for the Prevention of Venous Thromboembolism
2021 Standout
13 intermediate papers

Works of Gary E. Raskob being referenced

Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty
2020
A Comparison of Subcutaneous Low-Molecular-Weight Heparin with Warfarin Sodium for Prophylaxis against Deep-Vein Thrombosis after Hip or Knee Implantation
1993
and 21 more

Author Peers

Author Last Decade Papers Cites
Gary E. Raskob 12961 10851 4697 168 19.1k
David R. Anderson 11730 8132 5206 266 20.0k
J. Hirsh 9999 8650 5330 300 18.5k
Walter Ageno 13339 11130 3925 548 19.9k
Richard H. White 8299 5431 3863 241 15.5k
John A. Heit 22992 14795 9054 214 30.0k
Menno V. Huisman 19427 15073 5605 461 28.6k
William Geerts 14541 9454 6303 124 18.1k
Susan R. Kahn 19729 11249 9715 329 25.0k
Paolo Prandoni 20661 13227 8082 294 24.4k
Giancarlo Agnelli 11290 9001 3338 329 15.8k

All Works

Loading papers...

Rankless by CCL
2026